Every 8-K that Opko Health Inc. (OPK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OPK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPK filings page.
OPKO Health, Inc. entered into an amendment to its July 17, 2024 Note Purchase Agreement, issuing additional senior secured notes with an aggregate initial principal amount of $125,000,000. These Notes mature on July 17, 2044 and bear interest at the 3‑month SOFR, subject to a 4.0% per annum floor, plus 7.5% per annum, consistent with the existing notes.
Interest is payable quarterly and is determined by profit share payments EirGen Pharma Limited receives from Pfizer under a profit share arrangement. The Notes are secured by EirGen’s royalty interest in mazdutide under a license with Eli Lilly for sales in China, with related Mazdutide Payments capped at $187.5 million, subject to certain liabilities and expenses. Royalty and Mazdutide Payments are applied first to interest and then, if available, to principal reduction.
OPKO Biologics Ltd. and EirGen guarantee the obligations and have granted security interests in certain of their assets. The amended agreement includes customary negative and financial covenants and standard events of default. The Additional Notes were privately placed under exemptions from Securities Act registration.
OPKO Health reported second quarter 2026 results and extensive pipeline progress across oncology, infectious disease and metabolic programs. ModeX advanced multiple multispecific antibody and in vivo CAR T candidates into or toward Phase 1 trials, while OPK-88006 for MASH and long-acting growth hormone antagonist OPK8801001 moved forward, alongside oral hormone and obesity candidates co-developed with Entera and an expanded Nicoya agreement for RAYALDEE in Greater China.
Total revenue for the quarter was $163.5 million, up from $156.8 million a year earlier, with pharmaceuticals benefiting from $46.1 million of intellectual property and other revenue, including $29.4 million tied to Nicoya. Diagnostics services revenue declined to $74.5 million from $101.1 million after the Labcorp oncology asset sale, but segment operations generated income of $4.8 million.
Consolidated operating loss improved to $7.0 million and net loss to $8.4 million, or $0.01 per share, versus a $148.4 million loss in the prior-year quarter. Cash, cash equivalents, marketable securities and restricted cash totaled $314.4 million, and the company repurchased $13.2 million of stock in the quarter. Management issued 2026 revenue guidance of $560–$585 million and Q3 2026 revenue guidance of $131–$142 million.
OPKO Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected eleven directors, each receiving more votes "For" than "Against", including Phillip Frost, M.D. with 423,666,978 votes for and 40,175,942 against.
Stockholders approved the Company’s 2026 Equity Incentive Plan, with 440,096,997 votes for and 23,694,041 against. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 446,238,170 votes for and 17,487,326 against.
In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 535,070,921 votes for and 6,120,699 against. No other matters were considered or voted upon at the meeting.
OPKO Health reported first quarter 2026 results showing lower revenue but narrower losses as it reshapes its business. Total revenue was $124.2 million versus $149.9 million a year earlier, largely reflecting the prior sale of certain BioReference oncology assets.
Operating loss improved to $51.0 million from $67.2 million, and net loss narrowed to $54.8 million, or $0.07 per share, compared with a net loss of $67.6 million, or $0.10 per share. Pharmaceuticals revenue grew to $52.0 million, helped by higher international sales and increased NGENLA profit share, while diagnostics revenue declined to $72.2 million after the oncology divestiture.
Cash, cash equivalents, marketable securities and restricted cash totaled $341.9 million as of March 31, 2026. The company repurchased approximately $92.0 million of stock since its July 2025 authorization, including $4.8 million in the quarter, with about $108.0 million remaining available.
OPKO Health, Inc. has appointed Subbarao V. Uppaluri, Ph.D. as a new independent director, effective March 18, 2026. He will serve until the 2026 Annual Meeting of Stockholders and is expected to join the Compensation Committee.
Dr. Uppaluri previously served as OPKO’s Senior Vice President and Chief Financial Officer from 2007 to 2012 and later as a consultant. The board cites his independence under SEC and Nasdaq rules and notes there are no related-party transactions requiring disclosure. He fills a vacancy created by the passing of longtime director Dr. Richard Krasno and will receive the company’s standard non-employee director compensation and indemnification protections.
OPKO Health reported weaker results for the quarter and year ended December 31, 2025, while highlighting major new partnerships and a deepening pipeline. Fourth quarter revenue was $148.5 million versus $183.6 million a year earlier, with a net loss of $31.3 million, or $0.04 per share, compared with net income of $14.0 million in 2024.
For full year 2025, revenue fell to $606.9 million from $713.1 million, and net loss widened to $225.7 million from $53.2 million. The company signed a Regeneron collaboration with potential milestones exceeding $200 million per program and overall value above $1 billion, and reported progress across multiple ModeX antibody programs. Cash, cash equivalents and restricted cash were $369.1 million at year-end 2025. OPKO issued 2026 guidance calling for total revenue of $530–$560 million and total costs and expenses of $725–$750 million.
OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.
OPKO Health completed the sale of certain BioReference oncology and oncology-related laboratory testing business assets to Laboratory Corporation of America Holdings for up to $225,000,000 in cash. Of this amount, $192,500,000 was paid in cash at closing on September 15, 2025, with up to an additional $32,500,000 payable as contingent earnout consideration based on revenue from specified customer accounts. The company also issued a press release about the closing, furnished as Exhibit 99.1.